Phaxiam Therapeutics Sa (PHXM)

$3.1

Market is closed - opens 7 PM, 21 May 2024

Highlights

Market Capitalization
28.9M
Book Value
$6.03
Earnings Per Share (EPS)
-39.05
Profit Margin
-190.98%
Operating Margin TTM
-3232.01%
Return On Assets TTM
-15.05%
Return On Equity TTM
-38.62%
Revenue TTM
6.0M
Revenue Per Share TTM
1.87
Quarterly Revenue Growth YOY
-66.4%
Gross Profit TTM
0.0
EBITDA
-16.9M
Diluted Eps TTM
-39.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Phaxiam Therapeutics Sa(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
00
00
Hold
1
3
3
Sell
00
6
6

Technicals Summary

Sell

Neutral

Buy

Phaxiam Therapeutics Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Company Information

founded in 2004, erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. its first product, working by starving tumors, has completed its phase iii development and will provide a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia. the company has a production unit located in lyon with “pharmaceutical establishment” status. it has signed two distribution partnership agreements, with orphan europe-recordati (in europe) and teva (in israel).

Organization
Phaxiam Therapeutics Sa
Employees
49
CEO
Mr. Eric Soyer Ph.D.
Industry
Miscellaneous

FAQs